Abbott Laboratories ABT

101.29 0.22 0.22% as of 25 Sep
Market cap
$174.8B
P/E
32.8×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

Abbott Laboratories (ABT) Return on equity

Abbott Laboratories's return on equity over the twelve months to 30 June 2026 was 10.6%, down 2.4 percentage points from fiscal 2025 (13.0%). Over the past ten years it has ranged from 1.84% (fiscal 2017) to 30.9% (fiscal 2024); the current reading is higher than 45% of that period. That is above the Medical Devices industry median of −15.3% and above the Healthcare sector median of −32.0%.

Return on equity, annual

Annual

Period Return on equity Change (points)
FY2025 13.0% (17.95)
FY2024 30.9% 15.80
FY2023 15.1% (3.90)
FY2022 19.0% (1.48)
FY2021 20.5% 6.51
FY2020 14.0% 2.09
FY2019 11.9% 4.23
FY2018 7.66% 5.82
FY2017 1.84% (4.82)
FY2016 6.66% (13.93)

Against its own ten years

Low 1.84% High 30.9%
Ten-year median 14.0%
Current reading's percentile 45

Return on equity against peers

Company Return on equity
DXCM DexCom, Inc. compare 38.5%
GEHC GE HealthCare Technologies Inc. compare 19.2%
SYK Stryker Corporation compare 16.5%
BSX Boston Scientific Corporation compare 15.4%
STE STERIS plc compare 11.4%
ABT Abbott Laboratories 10.6%
MDT Medtronic PLC compare 10.6%
PHG Koninklijke Philips N.V. compare 10.2%
EW Edwards Lifesciences Corporation compare 9.42%
Medical Devices industry median −15.3%
Healthcare sector median −32.0%
Market median 1.76%

What Return on equity is

ROE shows how much profit a company earns for its shareholders on the equity they have in the business.

Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)

The full definition of Return on equity →

More on ABT